Abstract:Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer characterized by late diagnosis, lack of early symptoms and extensive metastasis. One of the foremost reasons for such startling statistics is the presence of a subpopulation of highly plastic stem-like cells within the tumor called cancer stem cells (CSCs). We have previously identified a distinct subset of these CSCs within the invasive front of patient tumors. This subset, called migrating cancer stem cells (miCSCs), is characterized by CD133+CXCR4+ expression and determines the metastatic phenotype of pancreatic cancer. Therefore, targeting CXCR4 may represent a potential therapeutic approach to lower metastatic burden in PDAC. Here, we examined the effect of endogenous human peptides EPI-X4 and other derivatives thereof as CXCR4 antagonist on (i) patient-derived primary pancreatic cancer cells and (ii) tumor-stroma crosstalk by using a dual culture system with pancreatic stellate cells. We established these peptides as novel therapeutic strategy for combating the metastatic activity of pancreatic cancer using combinatorial therapeutic approaches and testing different in vivo delivery system such as peptide fatty-acid (FA) conjugates and silica nanoparticles (Si-NP). Our results show that EPI-X4 as well as its derivatives (e.g., JM#21) strongly inhibited migratory capacity of primary pancreatic cancer cells towards the CXCR4 ligand CXCL12 in vitro. Thereby, JM#21 was identified as the most potent EPI-X4 derivate. Mechanistical analysis by western blot, gene expression and immunofluorescence revealed that JM#21 increased Cadherin-1 expression by suppression of Snail1 via inactivation of SHH pathway. Moreover, JM#21 decreased CXCL12-induced phosphorylation of AKT and IKBa as well as NANOG expression, which further suppressed self-renewal capacity and EMT in the tumor cells. Strikingly, JM#21 sensitized selected cell lines towards gemcitabine and paclitaxel. Furthermore, FA conjugated and Si-NP encapsulated JM#21 restricted miCSCs maintenance which was predominantly regulated via stellate cell secreted CXCL12. In serum conditions, both FA conjugated, and Si-NP encapsulated JM#21 was found to be stable and active, proving as a valuable delivery system for in vivo studies. In conclusion, our study reveals that targeting CXCR4/CXCL12 signaling axis using human endogenous EPI-X4 derivates particularly JM#21 inhibits tumor-stroma crosstalk which is paramount for the propagation and maintenance of miCSC. Particularly, we demonstrate, in both mechanistic and preclinical set up, that these peptides abrogate the metastatic capacity of patient-derived pancreatic cancer cells by selective targeted elimination of miCSCs. Moreover, tumor cells show increased susceptibility towards conventional treatment strategies enforcing EPI-X4 derivate as a novel combinatory therapy to treat metastatic pancreatic cancer. Citation Format: Kanishka Tiwary, Mirja Harms, Bastian Beitzinger, Roman Schmid, Syeda Inaas, Karolin Walter, Alexander Kleger, Mika Lindén, Thomas Seufferlein, Jan Münch, Patrick Christian Hermann. CXCR4 targeting endogenous human peptides eliminate migrating cancer stem cells by disrupting tumor-stroma crosstalk in pancreatic ductal adenocarcinomas [abstract]. In: Proceedings of the AACR Special Conference: Cancer Metastasis; 2022 Nov 14-17; Portland, OR. Philadelphia (PA): AACR; Cancer Res 2022;83(2 Suppl_2) nr B034.

Blockade of SDF-1/CXCR4 Signalling Inhibits Pancreatic Cancer Progression in Vitro Via Inactivation of Canonical Wnt Pathway.

Inhibition of Canonical Wnt Signaling Pathway in Pancreatic Cancer by Interfering CXCR4 in Vitro

Mechanisms by Which CXCR4/CXCL12 Cause Metastatic Behavior in Pancreatic Cancer

Sdf-1/Cxcr4 Signaling Induces Pancreatic Cancer Cell Invasion and Epithelial-Mesenchymal Transition in Vitro Through Non-Canonical Activation of Hedgehog Pathway

Cxcl12/Cxcr4 Axis Plays Pivotal Roles in the Organ-Specific Metastasis of Pancreatic Adenocarcinoma: A Clinical Study

Role of CXCL12/CXCR4 Signaling Axis in Pancreatic Cancer.

Effect of RNAi mediated CXCR4 knockdown on pulmonary metastasis of AsPC - 1 cells

Β-Catenin is a Promising Key Factor in the SDF-1/CXCR4 Axis on Metastasis of Pancreatic Cancer

SDF-1α/CXCR4 axis promotes migration and invasion of pancreatic cancer cells through inducing epithelial-mesenchymal transition

Aberrant Expression of CXCR4 and Β-Catenin in Pancreatic Cancer.

Silencing CXCR4 by RNA interference suppresses proliferation and invasion in pancreatic cancer cells

In Vitro Study on Stromal Cell Derived Factorl/chemokine Receptor 4 Axis That Involved in the Invasion of Human Pancreatic Cancer Cells

Abstract A22: CXCL12-CXCR4 chemotactic pathway modulates metastasis and perineural invasion in pancreatic cancer

SDF-1/CXCR4 Promotes Epithelial–mesenchymal Transition and Progression of Colorectal Cancer by Activation of the Wnt/β-catenin Signaling Pathway

Tissue‐resident CXCR4+ Macrophage As a Poor Prognosis Signature Promotes Pancreatic Ductal Adenocarcinoma Progression

Aberrant expression of CXCR4 significantly contributes to metastasis and predicts poor clinical outcome in breast cancer.

The Axis of CXCR4/SDF-1 Plays a Role in Colon Cancer Cell Adhesion Through Regulation of the AKT and IGF1R Signalling Pathways

CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response

CXCL12-CXCR7 axis contributes to the invasive phenotype of pancreatic cancer.

Abstract B034: CXCR4 targeting endogenous human peptides eliminate migrating cancer stem cells by disrupting tumor-stroma crosstalk in pancreatic ductal adenocarcinomas

Cxcl12-Cxcr4 Chemotactic Pathway Modulates Metastasis And Perineural Invasion In Pancreatic Cancer